Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery
Christian Brudy, Carlo Walz, Moritz Spiske, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14768-14785
Closed Access | Times Cited: 8
Discovery of fully synthetic FKBP12-mTOR molecular glues
Robin C. E. Deutscher, Christian Meyners, Maximilian Repity, et al.
Chemical Science (2025) Vol. 16, Iss. 10, pp. 4256-4263
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Advances in Personalized Oncology
Hiba Mechahougui, James Gutmans, Gina Colarusso, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2862-2862
Open Access | Times Cited: 5
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Qinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial
Marcelo V. Negrão, Alvaro G. Paula, David Molkentine, et al.
Clinical Cancer Research (2025)
Open Access
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Toshifumi Doi, Takeshi Ishikawa, Michihisa Moriguchi, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.
Sara Raji, Hamed Zaribafzadeh, Tyler Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer
Masashi Kanai
Cancers (2025) Vol. 17, Iss. 4, pp. 606-606
Open Access
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen
Alexander Kretzschmar
Onkologische Welt (2025) Vol. 16, Iss. 01, pp. 6-7
Closed Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Drugging mutant KRAS by disrupting binding to effectors and GTP
Adrienne D. Cox, Channing J. Der
Nature Cancer (2025)
Closed Access
RAS Pathway Mutations and Therapeutics in Vascular Anomalies
Sara Alharbi, Svatava Merkle, Adrienne M. Hammill, et al.
Pediatric Blood & Cancer (2025)
Open Access
Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer
Ahmed Mahmoud, Philip H. Choi, Christine Sukhwa, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The “three body solution”: Structural insights into molecular glues
Aidan C.A. Tomlinson, John E. Knox, Luc Brunsveld, et al.
Current Opinion in Structural Biology (2025) Vol. 91, pp. 103007-103007
Open Access
Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Progress in the Last Five Years
Osama Mosalem, Ahmed Abdelhakeem, Nayef Hikmat Abdel-Razeq, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Closed Access
Page 1 - Next Page

Scroll to top